For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...

In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...

Barcelona, Spain, 31 August: Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

March 6, 2009 (Munich, Germany) — More evidence that patients with a low platelet responsiveness to clopidogrel have an increased risk of stent thrombosis has come from a new study, with the ...

4 CMO Office, Qatar Orthopaedic and Sports Medicine Hospital, Qatar Correspondence to Dr Bruce Hamilton, Sports Medicine, High Performance Sport NZ, AUT/Millenium Institute of Sport and Health, ...